DLBC

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Monday, August 15, 2022
Lung cancer, U.S. Securities and Exchange Commission, DLBCL, Association, SYK, Risk, American Association, RECIST, University of California, Davis, MS, GLOBE, ORR, UC Davis Comprehensive Cancer Center, Population, Failure, Annual general meeting, Private Securities Litigation Reform Act, Cancer, B-cell lymphoma, Security (finance), UC, Income, NSCLC, DLBC, Neoplasm, Patient, Large-cell lung carcinoma, SAN, NFE2L2, WCLC, Program, Safety, Adenocarcinoma, Doctor of Philosophy, KRAS, AACR, Research, International Association, Webcast, KEAP1, CALA, Nasdaq, American Association for Cancer Research, Investor, Conference, Journal of Thoracic Oncology, ABC, VPS4A, Pharmaceutical industry, Cryptocurrency, VPS4B, NRF2, MD

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022.
  • Calithera plans to share data from this trial by the first quarter of 2023.
  • Research and development expenses for the second quarter 2022 were $7.8 million, compared to $12.8 million in the same period prior year.
  • General and administrative expenses for the second quarter 2022 were $3.6 million, compared to $4.5 million in the same period prior year.

Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Tuesday, May 10, 2022
U.S. Securities and Exchange Commission, Population, CD79, Private Securities Litigation Reform Act, Nasdaq, DLBC, GLOBE, American Association for Cancer Research, Neoplasm, Safety, Research, Common stock, NGS, Patient, Security (finance), Doctor of Philosophy, Association, Webcast, Risk, CD79B, American Association, Cancer, SYK, ABC, NSCLC, NFE2L2, CALA, Conference, ID, AACR, MYD88, Protein, SAN, Annual general meeting, Investor, Communications satellite, Pharmaceutical industry, Medical imaging, DLBCL, VPS4A, NRF2, VPS4B

SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the first quarter ended March 31, 2022.

Key Points: 
  • ET on Tuesday, May 10, 2022 --
    SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the first quarter ended March 31, 2022.
  • We made significant headway in the transfer of mivavotinib and sapanisertib materials to Calithera during the first quarter and are well into site start-up activities.
  • Calithera anticipates the first patient enrolled in the second quarter of 2022.
  • Calithera anticipates the first patient enrolled in this study in the second quarter of 2022.

Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

Retrieved on: 
Thursday, March 31, 2022
Private Securities Litigation Reform Act, Plasma, Head, ABC, Neoplasm, MD, NO, Association, American Association for Cancer Research, Nasdaq, GLOBE, Security (finance), Risk, Cystic fibrosis, Interest, American Association, Conference, Annual general meeting, CALA, U.S. Securities and Exchange Commission, Income, GCB, Investor, Investment, ID, Clinical trial, Arginine, AACR, Doctor of Philosophy, PD, Webcast, DLBC, ATPase, Black–Scholes model, SYK, Non-Hodgkin lymphoma, SAN, CD79, NFE2L2, Patient, Company, Cell, Common stock, VPS4B, Research, Cancer, Prevalence, VPS4A, Safety, Acquisition, Pharmaceutical industry, Medical imaging, Lithium, DLBCL, NRF2, MYD88, NSCLC

SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2021.
  • Research and development expenses for the fourth quarter of 2021 were $13.7 million, compared to $17.1 million for the same period last year.
  • General and administrative expenses for the fourth quarter of 2021 were $4.6 million, compared to $5.6 million for the same period last year.
  • Interest and other income, net for the fourth quarter of 2021 was none, compared to $0.1 million for the fourth quarter of 2020.

Yingli Pharma and MD Anderson Initiate Strategic Collaboration to Advance Development of Multiple Oncology Programs

Retrieved on: 
Thursday, January 20, 2022
National Cancer Institute, CRS, PTCL, Patient, KRAS, Research, National, Lymphoma, SAN, NMPA, Biotechnology, Clinical trial, PK, CA, MBA, Safety, Follicular lymphoma, GLOBE, U.S. News & World Report, NCI, Monroe Dunaway Anderson, Clinical Lymphoma, Myeloma & Leukemia, MD Anderson Cancer Center, P30, Program, Therapy, News, Tumor microenvironment, Education, Roy S. Herbst, MD, Cancer, T-cell lymphoma, ASCO, Anderson, Immunotherapy, DLBC, Hospital, Phase 1, Degenerative disease, University, Pharmaceutical industry

We look forward to working with the experts at MD Anderson, complementing our own expertise as we continue to build a well-rounded oncology pipeline.

Key Points: 
  • We look forward to working with the experts at MD Anderson, complementing our own expertise as we continue to build a well-rounded oncology pipeline.
  • Two of the programs supported by the collaboration will leverage favorable clinical trial findings collected from China-based studies.
  • We are pleased to be working with Yingli to initiate a Phase 2 clinical trial evaluating linperlisib in patients with PTCL, said principal investigator Swaminathan Iyer, M.D., professor of Lymphoma & Myeloma at MD Anderson.
  • In addition to advancing existing clinical programs, the collaboration also will focus on translational studies to further Yinglis discovery programs.